Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition’s research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
For more information about Volition, visit Volition’s website (http://www.volitionrx.com) or connect with us via:
Executive Vice President & Head of Investor Relations, VolitionRx Limited
Chief Financial Officer, Volition America, Inc.
Scott has more than 20 years of experience in the U.S. capital markets, investment banking, investor relations and corporate communication. Based in New York City, he directs a comprehensive capital markets program and investor relations strategy for Volition. His role includes strategic interactions with institutional investors, analysts, investment banks, and the financial media. Scott has served as Head of Investor Relations for four public companies, including Volition, and worked for several years as an investment banker in New York City. He earned his Bachelor of Science in Business Administration from Bryant University in Smithfield, RI, his Master of Arts and Doctor of Philosophy degrees from Brown University in Providence, RI, and his Certificate in Business from Columbia University in New York City.